{"id":"dapagliflozin-pioglitazone","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Genital mycotic infections"},{"rate":"3-8","effect":"Urinary tract infections"},{"rate":"5-15","effect":"Fluid retention / edema"},{"rate":"2-5","effect":"Weight gain"},{"rate":"1-3","effect":"Hypoglycemia"},{"rate":"2-5","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL429910","moleculeType":"Small molecule","molecularWeight":"408.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapagliflozin is an SGLT2 inhibitor that blocks reabsorption of glucose in the kidney, promoting glucose excretion in urine. Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity in muscle and adipose tissue. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.","oneSentence":"This combination drug reduces blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and activating PPAR-γ to improve insulin sensitivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:32:01.865Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT07391267","phase":"NA","title":"Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-01","conditions":"Chronic Kidney Diseases, MAFLD","enrollment":90},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07056699","phase":"PHASE3","title":"SGLT2i, Pioglitazone, and Ketone Production in T1D","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-01-30","conditions":"Type1diabetes","enrollment":24},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT06922656","phase":"PHASE4","title":"Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?","status":"NOT_YET_RECRUITING","sponsor":"Dasman Diabetes Institute","startDate":"2025-09-15","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT02969798","phase":"NA","title":"Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-01-01","conditions":"Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)","enrollment":700},{"nctId":"NCT07083401","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fed)","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-07-05","conditions":"Diabete Mellitus","enrollment":40},{"nctId":"NCT07083388","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fasting)","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-07-03","conditions":"Diabetes Mellitus","enrollment":52},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT03878459","phase":"PHASE4","title":"Dapagliflozin Plus Pioglitazone in T1DM","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-08-08","conditions":"Type 1 Diabetes Mellitus","enrollment":120},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT06649162","phase":"","title":"A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2024-09-30","conditions":"Type 2 Diabetes","enrollment":10000},{"nctId":"NCT05254626","phase":"PHASE2","title":"Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-08-01","conditions":"Non-alcoholic Steatohepatitis","enrollment":100},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT04885712","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-05-28","conditions":"Type2 Diabetes","enrollment":378},{"nctId":"NCT04419337","phase":"PHASE2","title":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Stroke","enrollment":200},{"nctId":"NCT05591235","phase":"PHASE3","title":"Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-11","conditions":"Type2diabetes, Insulin Resistance","enrollment":60},{"nctId":"NCT05411965","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-04-28","conditions":"Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT04287387","phase":"PHASE4","title":"Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-02","conditions":"Type2 Diabetes Mellitus","enrollment":180},{"nctId":"NCT03794518","phase":"PHASE3","title":"Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF","status":"UNKNOWN","sponsor":"Hamad Medical Corporation","startDate":"2019-03","conditions":"Risk Reduction","enrollment":648},{"nctId":"NCT01095666","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":1484},{"nctId":"NCT00683878","phase":"PHASE3","title":"Add-on to Thiazolidinedione (TZD) Failures","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Type 2 Diabetes","enrollment":972},{"nctId":"NCT00680745","phase":"PHASE3","title":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":597}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dapagliflozin/Pioglitazone","genericName":"Dapagliflozin/Pioglitazone","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug reduces blood glucose by inhibiting SGLT2 to increase urinary glucose excretion and activating PPAR-γ to improve insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}